NPCE · NeuroPace Inc
$14.77
+0.26 (+1.79%)
At close · Aug 14
Market Cap
$506.97M
Shares
34.32M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.77
Open$14.46
Day$14.29–14.80
52W close$8.25–19.29
Avg vol 30d212K
Short int822K · 2.4% float · 3.9d
Short vol48%
Last earningsAug 11, 2026
DataApr 2021–Aug 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 7, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−3%
below
Price vs 50-day avg
−5%
below
RSI (14)
49
neutral
MACD trend
Positive
52-week position
59%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−8%
trailing
6-month return
+1%
trailing
YTD return
−4%
this year
Relative strength
−12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $15 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +20 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.40% of float · ▼ -6.0% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
113 holders — near 3-yr high, broad support
Squeeze score
41
elevated · 0–100
Fundamentals
Revenue growth
+25%
Y/Y
Gross margin
77%
expanding
EPS growth
+29%
Y/Y
Free cash flow
$-11.3M
Balance sheet
$37.2M
net debt
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 11, 2026
Total revenue
· full year 2026
Initiated
$99.5M – $101.5M
prior FY $99.99M
midpoint +0.5% Y/Y
Non-GAAP gross margin
· full year 2026
Non-GAAP
Initiated
82% – 83%
Adjusted EBITDA
· full year 2026
Non-GAAP
Initiated
$-8.5M – $-7.5M
Non-GAAP operating expenses
· full year 2026
Non-GAAP
Initiated
$90M – $92M
Prior guidance
period ended
· from the 8-K filed Mar 3, 2026
Total revenue
· first quarter 2026
$21M – $22M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−3%
Neutral
Price vs 50-day avg
−5%
Neutral
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
59%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $15 › 200d $15 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +20 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.40% of float · ▼ -6.0% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
113 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8
Now $15 · 59%
Range high $19
vs 200-day avg -3%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA from continuing operations (Non-GAAP) non-GAAP | -6.04M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA loss non-GAAP | -$2.8M | second quarter of 2026 | — |
| Non-GAAP general and administrative expense non-GAAP | $4.1M | second quarter of 2026 | — |
| Non-GAAP gross margin non-GAAP | 83.4% | second quarter of 2026 | — |
|
|
|||
| Non-GAAP loss from operations non-GAAP | -$2.8M | second quarter of 2026 | — |
| Non-GAAP net loss non-GAAP | -$3.9M | second quarter of 2026 | — |
| Non-GAAP operating expenses non-GAAP | $21.9M | second quarter of 2026 | — |
| Non-GAAP research and development expense non-GAAP | $6.3M | second quarter of 2026 | — |
| Non-GAAP sales and marketing expense non-GAAP | $11.5M | second quarter of 2026 | — |
| Adjusted EBITDA non-GAAP | $0.9M | the fourth quarter of 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NPCE
this stock
NeuroPace Inc
|
$506.97M | -4.3% | +25.1% | — | 2.4% |
|
ABT
Abbott Laboratories
|
$193.78B | -11.2% | +5.7% | 31.2 | 1.3% |
|
SYK
Stryker Corp
|
$130.11B | -3.5% | +11.2% | 35.2 | 2.2% |
|
MDT
Medtronic plc
|
$116.83B | -5.0% | +8.4% | 24.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$75.11B | -45.6% | +12.5% | 21.0 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NPCE | -0.4% | -8.2% | +1.4% | +14.6% | -4.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -0.8% | -12.6% | -12.3% | +10.7% | -18.2% |
Key facts
CIK
1528287
CUSIP
641288105
13F (30d)
114 filings
112 filers
Visit website
Investor relations